Clinical Read2026-06-01

Olverembatinib (HQP1351) with blinatumomab

Ascentage Pharma Group InternationalAAPG
Indication
Lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)
Stage
phase1
Event
Phase 1